Itaconix (AIM: ITX) shares surge as revenue guidance rises to at least $14.8m

Itaconix plc (AIM: ITX) reported record unaudited revenue of $8.3 million for the six months ended 30 June 2026, an increase of 72% from the corresponding period and 46% from the second half of 2025. The plant-based specialty polymer company now expects full-year revenue of at least $14.8 million, compared with the $13.3 million analyst forecast understood by the board before the update. Itaconix also maintained its expectation of delivering a small positive EBITDA result despite investing in additional employees and product development. The shares rose more than 23% during the 17 July session and reached a new 52-week high, reflecting increased confidence that rapid revenue growth may finally translate into operating profitability.

The scale of the first-half increase represents a material acceleration from an already strong 2025 financial year. Itaconix generated annual revenue of $10.5 million last year, meaning the company produced almost four-fifths of that amount during the first six months of 2026 alone.

Growth was reported across all major product segments. Performance Ingredients benefited from repeat orders, new detergent customers and increased demand in Europe, the Middle East and Africa and North America. SPARX Formulated Solutions also expanded as more contract manufacturers used Itaconix formulations and additional ingredients in solid unit-dose dishwashing and laundry products.

The central question is no longer whether Itaconix can generate commercial demand for its polymer technology. It is whether reorder rates, customer diversification and margin discipline can make the current growth repeatable enough to establish a durable, cash-generating specialty ingredients business.

Why does Itaconix’s 72% first-half revenue growth represent a strategic inflection point?

Itaconix has spent several years attempting to convert a proprietary polymer platform into commercial scale. The latest result suggests that the company may be moving beyond the stage where isolated customer launches and product trials dominate the investment case.

First-half revenue of $8.3 million was $3.5 million higher than the $4.8 million generated in the first half of 2025. It was also $2.6 million above the $5.7 million produced during the second half of last year.

This sequential growth matters because annual comparisons can sometimes be flattered by a weak historical base. Itaconix has now reported a series of progressively larger half-year revenue periods, suggesting that demand is building rather than arriving through one exceptional contract.

Management said growth occurred across all major product segments. Existing customers increased reorder volumes, while new customers began purchasing ingredients for unit-dose dishwashing and laundry products.

The combination is strategically important. New customer wins expand the addressable revenue base, but repeat orders indicate whether products are gaining recurring commercial use. Specialty ingredient companies become more valuable when customer formulations, manufacturing processes and retail products depend on their technology over extended periods.

Itaconix’s polymers are designed to perform functions such as scale inhibition, dispersion, chelation, odour control, foam enhancement and film formation. Once an ingredient is incorporated into a commercial detergent or consumer product, changing suppliers may require reformulation, testing and customer approval.

That can create attractive customer retention characteristics, although Itaconix has cautioned that reorder rates for some recent business are not yet firmly established. The raised guidance therefore reflects stronger current trading without claiming that every new revenue stream has already become predictable.

How demanding is Itaconix’s new minimum FY26 revenue target of $14.8 million?

The new revenue guidance requires Itaconix to generate at least $6.5 million during the second half of 2026. That would represent a sequential decline from the record first half but an increase of approximately 14% from the $5.7 million achieved during the second half of 2025.

The structure of the guidance appears deliberately cautious. Management is not assuming that first-half revenue will simply repeat during the second half. It has acknowledged that reorder patterns have not yet been firmly established across the expanded customer base.

This matters because detergent ingredient demand can be affected by customer inventory decisions, retailer launches, contract manufacturing schedules and the timing of bulk orders. A customer may place a significant initial order ahead of a product launch and then take several months before establishing a stable replenishment cycle.

The $14.8 million floor nevertheless implies annual growth of at least 41% from the $10.5 million reported in 2025. It also places the company around $1.5 million above the previous market revenue expectation identified by the board.

The stronger outlook therefore represents more than a timing shift between halves. It suggests that commercial adoption has progressed faster than previously incorporated into external forecasts.

The September interim results should provide more detail on whether first-half revenue was evenly distributed or concentrated in several large orders. Investors will also need information on current orders, post-period trading and the number of customers contributing meaningful recurring revenue.

A further guidance increase later in the year would require evidence that new customers are reordering faster than expected. Conversely, the present guidance already allows for some moderation after the unusually strong first half.

Can Itaconix achieve positive EBITDA without sacrificing investment in future growth?

Itaconix continues to expect a small positive EBITDA result for 2026. This would represent a significant financial milestone after an adjusted EBITDA loss of $600,000 in 2025 and a loss of $1.8 million in 2024.

The improvement is being driven by operating leverage. Revenue has expanded much faster than the company’s fixed administrative and development cost base, allowing a larger gross profit contribution to absorb corporate expenditure.

Itaconix expects the first-half gross profit margin to remain around 36%, broadly consistent with the 35% achieved in 2025. Maintaining the margin while revenue increased 72% indicates that growth has not been purchased through broad price discounting or uncontrolled raw-material costs.

The company credited robust management of raw materials and supply chains. That is particularly relevant because Itaconix manufactures in the United States, sells internationally and sources certain inputs from global suppliers.

Positive EBITDA will not automatically mean positive free cash flow or statutory profitability. Itaconix will continue incurring depreciation, amortisation, working-capital movements and development expenditure, while the timing of customer payments and inventory purchases can materially influence cash generation.

The company is also investing in headcount and product development. Management appears to be balancing near-term profitability against the need to support customer projects and create additional revenue opportunities.

That strategy is commercially sensible if the additional expenditure produces recurring sales at attractive margins. It becomes less compelling if the company expands costs in anticipation of customers whose projects remain in extended development cycles.

The September results should therefore show whether operating expenses are increasing more slowly than gross profit. A positive EBITDA result created through scalable revenue growth would be more valuable than one produced by postponing commercially necessary investment.

Why are Performance Ingredients and SPARX Formulated Solutions economically different businesses?

Itaconix’s revenue comes primarily from Performance Ingredients and SPARX Formulated Solutions, but the two activities have different margin and strategic characteristics.

Performance Ingredients sells proprietary specialty polymers used by customers in their own formulations. In 2025, the segment generated approximately 73% of group revenue and achieved a weighted average gross profit margin of 41%.

This is the economically stronger part of the business. Proprietary ingredients can command attractive pricing when they provide customers with multiple performance functions or allow products to meet environmental and safety objectives.

SPARX Formulated Solutions generated approximately 27% of 2025 revenue but carried a lower weighted average gross profit margin of 17%. Itaconix develops formulations and sells additional ingredients required by contract manufacturers to produce completed detergent products.

SPARX can accelerate market adoption by giving brands and manufacturers a more complete formulation rather than asking them to build a product around one ingredient. It can therefore function as a commercial bridge that expands demand for Itaconix polymers.

However, growth in lower-margin formulated solutions could dilute the group margin if it outpaces Performance Ingredients. The strategic value depends on whether SPARX creates proprietary ingredient demand, establishes customer relationships and encourages contract manufacturers to adopt Itaconix formulations at larger scale.

The stable first-half group margin suggests that the current revenue mix remained manageable. Investors should still monitor the contribution from each business because similar top-line growth rates can produce very different gross profit outcomes.

The ideal scenario is that SPARX opens doors while Performance Ingredients captures a larger share of the long-term economics. Itaconix must avoid becoming primarily a lower-margin reseller of ingredients sourced from other suppliers.

How important are detergent customers in Europe and North America to Itaconix’s growth?

Dishwashing and laundry detergents remain the company’s most commercially established applications. Performance Ingredients delivered growth in both Europe, the Middle East and Africa and North America during the first half.

Existing customers increased orders, while Itaconix added a new unit-dose dishwashing customer in Europe and a new unit-dose laundry customer in North America.

The geographic balance has become more diversified. In 2025, North America represented 62% of group revenue, while Europe, the Middle East and Africa accounted for 38%. Revenue from the European region more than doubled during that year.

Diversification reduces dependence on one geography, but the company still carries meaningful customer concentration. Its three largest customers accounted for 48% of 2025 revenue, up from 40% in 2024.

Rapid growth can temporarily increase concentration when a small number of customers scale faster than the broader base. The risk is that changes in purchasing volumes, product performance or contract-manufacturing arrangements at one large customer could create volatility.

Itaconix’s task is therefore to add customers without merely replacing one concentrated exposure with another. Management has highlighted a pipeline of detergent brands, contract manufacturers and new product programmes, but revenue diversity must eventually be visible in the reported numbers.

The presence of both new customers and stronger reorder volumes is constructive. The next stage is demonstrating that the largest customers continue growing while their percentage share of total revenue gradually declines.

What does the first plastic-free tablet supply agreement add to the investment case?

Itaconix announced its first customer supply agreement for its proprietary eight-gram plastic-free dish detergent tablet on 14 July, three days before the trading update.

The unnamed North American brand is expected to launch the tablets in retail outlets by the end of 2026. Initial supply will use pilot-scale tableting capacity at Itaconix’s North American Innovation Center.

The product combines Itaconix TSI polymers with tablet-press technology supplied by Bonals Technologies. The companies recently extended their collaboration through December 2028.

The agreement is strategically relevant because it moves Itaconix beyond supplying ingredients into a completed product format that brands can take towards retail. It also gives the company an opportunity to demonstrate consumer performance, manufacturing reliability and commercial demand for a compact plastic-free alternative.

However, pilot-scale production is not the final commercial model. The larger opportunity depends on contract manufacturers installing or using high-speed Bonals equipment capable of producing tablets at greater volume and lower unit cost.

The first customer agreement should therefore be viewed as market validation rather than a major revenue event on its own. Its value lies in generating operating data, retailer interest and additional brand discussions.

A successful launch could help Itaconix persuade manufacturers that its formulation has sufficient demand to justify production investment. A slow launch would not necessarily invalidate the technology, but it could delay the transition from pilot manufacturing to scalable supply.

Can paints and agriculture reduce Itaconix’s dependence on household detergents?

Itaconix is developing longer-term opportunities through BIO*Asterix specialty monomers and binders for paints and BioVail ingredients for crop production.

These markets could substantially increase the company’s addressable opportunity. Paints, coatings and agricultural inputs use large volumes of functional materials, and manufacturers are under pressure to improve performance while reducing dependence on petrochemical ingredients.

The challenge is that new specialty chemicals usually require lengthy evaluation. Customers must test compatibility, performance, stability, safety and cost before changing established formulations or manufacturing processes.

Detergents are therefore likely to remain the principal revenue and profit driver during the near term. BIO*Asterix and BioVail should be treated as strategic options rather than material contributors to the FY26 guidance.

Itaconix’s stronger core performance gives it more room to pursue these opportunities without relying entirely on external capital. That is a meaningful improvement from earlier stages when development expenditure was supported by a smaller commercial base.

Management must still maintain discipline. Advancing too many applications simultaneously could increase costs and distract technical resources from markets already demonstrating repeatable demand.

The strongest model would use profitable detergent revenue to fund measured expansion into selected higher-value markets. Itaconix does not need every development programme to succeed, but it needs enough commercial evidence to justify continued investment.

Why did Itaconix shares reach a new 52-week high after the trading update?

Itaconix shares rose more than 23% during the 17 July session, with the quoted price reaching approximately 142 pence to sell and 147 pence to buy. The stock traded as high as 150 pence, establishing a new 52-week high.

More than 370,000 shares had changed hands by early afternoon, substantially above the company’s typical recent trading activity. At the quoted price, Itaconix had a market capitalisation of approximately £19.5 million.

The reaction coincided with a clear earnings catalyst. Revenue exceeded the previous trajectory, full-year guidance was raised and management maintained its expectation of crossing into positive EBITDA.

The share-price rise also reflects the valuation sensitivity of a small company approaching profitability. When fixed costs are relatively stable, incremental gross profit can produce a disproportionately large improvement in EBITDA and cash generation.

However, one record half does not remove execution risk. The stock is now pricing in greater confidence that customer orders will repeat and that the company can protect margins while investing for growth.

The next rerating would probably require another increase in revenue expectations, firmer evidence of positive cash generation or confirmation that new product categories are moving into commercial scale.

A weaker second half could reverse some of the optimism if investors conclude that first-half growth included orders that will not recur at the same rate. The September interim results will therefore be important even though the company has already disclosed the headline revenue and margin figures.

What evidence will confirm that Itaconix has built a durable specialty ingredients business?

Itaconix has materially improved its position. Revenue has accelerated, gross margins have remained stable and adjusted EBITDA is expected to turn positive.

What remains unresolved is the quality and predictability of that growth. Management has explicitly acknowledged that reorder rates are not yet firmly established across all recent business.

The next evidence should come from customer retention, revenue diversification and cash conversion. Itaconix needs a larger number of customers generating recurring orders without allowing the largest accounts to dominate group performance.

Margin composition will also matter. Strong growth in proprietary Performance Ingredients would support a more attractive long-term earnings profile than expansion led predominantly by lower-margin formulated solutions.

Positive EBITDA will be an important milestone, but sustained operating cash generation would provide stronger evidence that the company can finance growth without repeated equity issuance.

The September 2026 interim results should reveal whether the first-half surge was broad, profitable and cash-efficient. The most important test is whether Itaconix can convert its $14.8 million revenue floor into the beginning of a repeatable profitability cycle rather than a single exceptional year.

What are the key takeaways from Itaconix’s record first-half trading update?

• Itaconix generated record unaudited first-half revenue of $8.3 million, representing growth of 72% from the corresponding period.
• Revenue increased 46% compared with the second half of 2025, extending the company’s sequence of record half-year performances.
• The board now expects FY26 revenue of at least $14.8 million, above the previous analyst forecast of $13.3 million.
• Itaconix continues to expect a small positive EBITDA result while investing in additional employees and product development.
• The first-half gross profit margin is expected to remain around 36%, indicating that rapid sales growth has not materially weakened pricing or supply-chain economics.
• Performance Ingredients benefited from repeat orders and new detergent customers in Europe and North America.
• SPARX Formulated Solutions expanded through greater use of Itaconix formulations in solid unit-dose dishwashing and laundry products.
• The company’s first plastic-free dish tablet customer agreement provides commercial validation, although scalable production still depends on contract-manufacturing adoption.
• Customer concentration remains a material consideration after the three largest customers generated 48% of 2025 revenue.
• Itaconix shares rose more than 23% and reached a new 52-week high as the market reassessed the company’s path towards profitability.